| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10914898 | Molecular Oncology | 2013 | 13 Pages |
Abstract
⺠Response to bevacizumab was investigated in xenograft models of two common breast cancer subtypes. ⺠Combination treatment with bevacizumab had the strongest growth inhibiting effect in basal-like tumors. ⺠Most efficient treatment accompanied with the largest magnitude of gene expression changes. ⺠Hypoxia was increased with bevacizumab treatment in basal-like tumors. ⺠Levels of glycerophosphocholine showed opposite patterns of response in the two models.
Keywords
IQRKEGGPChoFDATCHOXenograftSCIDGPCMRSTSPFDRGEOPFsFeature extractionProgression free survivaloverall survivalbevacizumabanalysis of varianceANOVAinter quartile rangeKyoto Encyclopedia of Genes and GenomesFood and Drug AdministrationBreast cancermagnetic resonance spectroscopyphosphocholineMetabolomicsTranscriptomicsERETICfalse discovery rateGene ontologyGene Expression Omnibustotal cholineglycerophosphocholine
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Eldrid Borgan, Evita M. Lindholm, Siver Moestue, Gunhild M. Mælandsmo, Ole Christian Lingjærde, Ingrid S. Gribbestad, Anne-Lise Børresen-Dale, Olav Engebraaten, Therese Sørlie,